Page 134 - Demo

Chapter 513221. Jacquemont S, Berry-Kravis E, Hagerman R, Von Raison F, Gasparini F, Apostol G, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology. 2014. 22. Jansen-Van Der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, et al. Rare disease registries: Potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. 2018. 23. Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019. 24. Elgersma Y, Sonzogni M. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome. Vol. 63, Developmental Medicine and Child Neurology. 2021. 25. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123. 26. Müller AR, Brands MM, van de Ven PM, Roes KC, Cornel MC, van Karnebeek CD, et al. The Power of 1: Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders. Neurology. 2021. 27. Hessl D, Sansone SM, Berry-Kravis E, Riley K, Widaman KF, Abbeduto L, et al. The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions. J Neurodev Disord. 2016;8(1). 28. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4(152). 29. Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, et al. Arbaclofen in fragile X syndrome: Results of phase 3 trials. J Neurodev Disord. 2017;9(1). 30. Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati E V., Sweeney JA, et al. Fragile X targeted pharmacotherapy: Lessons learned and future directions. Vol. 9, Journal of Neurodevelopmental Disorders. 2017. 31. Wilson IB. Linking Clinical Variables With Health-Related Quality of Life. JAMA. 1995;273(1). 32. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Vol. 169, Annals of Internal Medicine. 2018. 33. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Humana y Diet. 2016. 34. Poletti V, Biffi A. Gene-Based Approaches to Inherited Neurometabolic Diseases. Vol. 30, Human Gene Therapy. 2019. 35. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016.36. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2018;96. 37. Terwee CB, Zuidgeest M, Vonkeman HE, Cella D, Haverman L, Roorda LD. Common patientreported outcomes across ICHOM Standard Sets: the potential contribution of PROMIS®. BMC Med Inform Decis Mak. 2021;21(1). 38. Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2017. 39. Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, D’Ardhuy XL, et al. Outcome measures for clinical trials in down syndrome. Am J Intellect Dev Disabil. 2017;122(3). 40. Endo-ERN. The ERICA Patient Reported Outcome Measures (PROMs) Repository [Internet]. [cited 2023 Jun 3]. Available from: https://endo-ern.eu/the-erica-patient-reported-outcomemeasures-proms-repository/41. Shields RH, Kaat AJ, McKenzie FJ, Drayton A, Sansone SM, Coleman J, et al. Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology. 2020. Annelieke Muller sHL.indd 132 14-11-2023 09:07